Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Two phase 3 trials with identical design, LIBERTY AD SOLO 1 (NCT02277743) and LIBERTY AD SOLO 2 (NCT02277769), confirmed dupilumab efficacy and safety versus placebo in adults with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To report a pooled analysis of these trials to further explore dupilumab's effects on AD clinical parameters, patient-reported outcomes (PROs), symptoms of anxiety/depression, health-related quality of life (HRQoL), and safety. METHODS: A pooled analysis of two 16-week phase 3 studies in adults with moderate-to-severe AD (N = 1379) inadequately controlled with/inadvisable for topical medications, randomized to dupilumab 300 mg once weekly (qw), every 2 weeks (q2w), or placebo. RESULTS: Dupilumab significantly improved all pre-specified efficacy endpoints versus placebo (P < 0.0001), including clinical severity outcomes and PROs, symptoms of anxiety/depression, and HRQoL, consistent with previously published results. In post-hoc analyses, among patients reporting at least some baseline pain/discomfort on the EuroQoL-5D, no pain/discomfort at Week 16 was reported by 43%/46%/14% of dupilumab qw/q2w/placebo-treated patients (P < 0.0001). The distribution of dupilumab-treated patients within pre-defined score categories on the Investigator's Global Assessment (0-1/2/3/4) and Eczema Area and Severity Index (≥90%/≥75-<90%/≥50-<75%/<50%) steadily and consistently improved over time versus marginal changes with placebo. Dupilumab significantly improved pruritus within 1-3 days of treatment initiation. No new safety signals were observed. Injection-site reactions and conjunctivitis were more common with dupilumab; AD exacerbation and non-herpetic skin infections more frequent with placebo. CONCLUSIONS: Dupilumab versus placebo significantly improved objective AD signs, subjective PROs, symptoms of anxiety/depression, and HRQoL, with a favorable benefit-risk profile in adults with moderate-to-severe AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Self-citationMechanism of HBD-3 deficiency in atopic dermatitis
Howell, M. D., Boguniewicz, M., Pastore, S., Novak, N., Bieber, T., Girolomoni, G., & Leung, D. Y. M. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.08.008 · Cited by 208
Self-Reported Population Health: An International Perspective Based on EQ-5D
Szende, A., Janssen, M. B., Cabasés, J. M., & Ramos Goñi, J. M. (2013) · Value in Health · doi:10.1016/j.jval.2013.08.812 · Cited by 196
Chalmers, J. R., Simpson, E., Apfelbacher, C. J., Thomas, K. S., Kobyletzki, L., Schmitt, J., Singh, J. A., Svensson, Å., Williams, H. C., Abuabara, K., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14773 · Cited by 125
Self-citation
Cited by
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Hamilton, J. D., Harel, S., Swanson, B. N., Brian, W., Chen, Z., Rice, M. S., Amin, N., Ardeleanu, M., Radin, A., Shumel, B., et al. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13954 · Cited by 192
Self-citationEfficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46
“common in treatment groups than placebo) [43].”
Shi, V. Y., Chamberlain, W., Siegfried, E., Kraff-Cooper, C., Beckman, K., Lio, P., Paller, A. S., & Simpson, E. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.01.043 · Cited by 18
“…with higher conjunctivitis rates while on a lower AD treatment frequency/dose (Supplementary Table I, available via Mendeley at https://doi.org/10.17632/ 43-47 local undertreatment, possibly due to higher target burden or lower tissue distribution, has been proposed to influence this observation.”
InfluentialSelf-citationThe role of lebrikizumab in the treatment of atopic dermatitis in the adult population
Prajapati, S., Fardos, M., Desai, A. D., & Feldman, S. R. (2023) · Immunotherapy · doi:10.2217/imt-2023-0066 · Cited by 4
Metadata
- Authors
- Thaçi, D., L. Simpson, E., Deleuran, M., Kataoka, Y., Chen, Z., Gadkari, A., Eckert, L., Akinlade, B., Graham, N. M. H., Pirozzi, G., & Ardeleanu, M.
- Venue
- Journal of Dermatological Science
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 94
- Issue
- 2
- Pages
- 266-275
- ISSN
- 0923-1811 (ISSN-L)
- OpenAlex
- W2921337698
- Cited by
- 188
- References
- 8
- FWCI
- 18.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). https://app.cochat.ai/papers/10.1016/j.jdermsci.2019.02.002
- The paper
- Thaçi, D., L. Simpson, E., Deleuran, M., Kataoka, Y., Chen, Z., Gadkari, A., Eckert, L., Akinlade, B., Graham, N. M. H., Pirozzi, G., & Ardeleanu, M. (2019). Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Journal of Dermatological Science. https://doi.org/10.1016/j.jdermsci.2019.02.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.